

Christoph Wanner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2158712/publications.pdf>

Version: 2024-02-01

216
papers

33,431
citations

23500

58
h-index

3815

178
g-index

220
all docs

220
docs citations

220
times ranked

23501
citing authors

#	ARTICLE	IF	CITATIONS
1	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 2117-2128.	13.9	8,841
2	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	13.9	2,821
3	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 323-334.	13.9	2,809
4	Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. <i>New England Journal of Medicine</i> , 2005, 353, 238-248.	13.9	2,363
5	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet</i> , 2011, 377, 2181-2192.	6.3	2,087
6	Review on uremic toxins: Classification, concentration, and interindividual variability. <i>Kidney International</i> , 2003, 63, 1934-1943.	2.6	1,379
7	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 69.	3.8	830
8	Chronic kidney disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17088.	18.1	558
9	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018, 41, 356-363.	4.3	534
10	Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. <i>Kidney International</i> , 2013, 84, 1096-1107.	2.6	513
11	KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. <i>Kidney International</i> , 2014, 85, 1303-1309.	2.6	452
12	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet</i> , 2019, 393, 1937-1947.	6.3	408
13	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 119-129.	1.6	347
14	SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 90-100.	0.9	333
15	Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 610-621.	5.5	301
16	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	2.6	232
17	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 128-139.	5.5	223
18	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. <i>European Heart Journal</i> , 2018, 39, 363-370.	1.0	199

#	ARTICLE	IF	CITATIONS
19	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME [®] , [†]). <i>Cardiovascular Diabetology</i> , 2014, 13, 102.	2.7	198
20	Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2014, 129, 999-1008.	1.6	197
21	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 749-761.	1.4	196
22	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv15-iv25.	0.4	180
23	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. <i>Circulation</i> , 2021, 143, 310-321.	1.6	168
24	GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1735-1745.	3.0	163
25	Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1867-1876.	3.0	157
26	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2755-2769.	3.0	148
27	Performance of hemodialysis with novel medium cut-off dialyzers. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw310.	0.4	140
28	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	2.9	139
29	Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics. <i>Kidney and Blood Pressure Research</i> , 2004, 27, 259-266.	0.9	131
30	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. <i>Circulation</i> , 2019, 139, 351-361.	1.6	126
31	Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2220-2228.	2.2	122
32	European expert consensus statement on therapeutic goals in Fabry disease. <i>Molecular Genetics and Metabolism</i> , 2018, 124, 189-203.	0.5	122
33	The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. <i>Molecular Genetics and Metabolism Reports</i> , 2019, 19, 100454.	0.4	120
34	Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. <i>Circulation</i> , 2018, 138, 1904-1907.	1.6	117
35	Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. <i>European Heart Journal</i> , 2015, 36, ehv352.	1.0	116
36	Mediterranean diet as the diet of choice for patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 725-735.	0.4	114

#	ARTICLE	IF	CITATIONS
37	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017, 48, 1218-1225.	1.0	112
38	High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 288-293.	0.4	111
39	Characterization and implications of the initial estimated glomerular filtration rate \hat{eGFR}^{TM} upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. <i>Kidney International</i> , 2021, 99, 750-762.	2.6	111
40	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 2313-2324.	13.9	108
41	Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β : data from the Fabry Registry. <i>Journal of Medical Genetics</i> , 2016, 53, 495-502.	1.5	101
42	Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 248-261.	1.4	97
43	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. <i>Circulation</i> , 2022, 145, 1460-1470.	1.6	97
44	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2014, 86, 1244-1252.	2.6	91
45	Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. <i>American Journal of Kidney Diseases</i> , 2015, 66, 441-449.	2.1	91
46	Taming the chronic kidney disease epidemic: a global view of surveillance efforts. <i>Kidney International</i> , 2014, 86, 246-250.	2.6	84
47	Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1028-1037.	0.4	81
48	Use of vascular access for haemodialysis in Europe: a report from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1956-1964.	0.4	79
49	Analysis from the EMPA-REG OUTCOME [®] trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. <i>Kidney International</i> , 2019, 96, 489-504.	2.6	77
50	Glycated Hemoglobin and Risk of Death in Diabetic Patients Treated With Hemodialysis: A Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2014, 63, 84-94.	2.1	72
51	Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 457-469.	1.4	70
52	Rationale, design, and baseline characteristics of the Cardiovascular safety and Renal Microvascular outcome study with LINagliptin (CARMELINA [®]): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. <i>Cardiovascular Diabetology</i> , 2018, 17, 39.	2.7	70
53	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , 2020, 22, 126-135.	2.9	67
54	Renal replacement therapy for rare diseases affecting the kidney: an analysis of the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv1-iv8.	0.4	65

#	ARTICLE	IF	CITATIONS
55	The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease â€œ A systematic literature review by a European panel of experts. <i>Molecular Genetics and Metabolism</i> , 2019, 126, 224-235.	0.5	65
56	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859.	2.6	65
57	Fabry disease and the heart. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2015, 29, 195-204.	2.2	62
58	Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME trial. <i>Journal of Diabetes Investigation</i> , 2019, 10, 760-770.	1.1	61
59	Factors Influencing the Decision to Start Renal Replacement Therapy: Results of a Survey Among European Nephrologists. <i>American Journal of Kidney Diseases</i> , 2012, 60, 940-948.	2.1	58
60	Thyroid Function, Cardiovascular Events, and Mortality in Diabetic Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2014, 63, 988-996.	2.1	57
61	Quantification of HDL Proteins, Cardiac Events, and Mortality in Patients with Type 2 Diabetes on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 224-231.	2.2	54
62	Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry. <i>American Journal of Kidney Diseases</i> , 2015, 66, 613-620.	2.1	52
63	Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis. <i>Molecular Genetics and Metabolism</i> , 2015, 114, 242-247.	0.5	51
64	The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease â€œ A systematic literature review by a European panel of experts. <i>Molecular Genetics and Metabolism</i> , 2019, 126, 212-223.	0.5	50
65	Optimization of the convection volume in online post-dilution haemodiafiltration: practical and technical issues. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 191-198.	1.4	49
66	Empagliflozin in women with type 2 diabetes and cardiovascular disease â€œ an analysis of EMPA-REG OUTCOME. <i>Diabetologia</i> , 2018, 61, 1522-1527.	2.9	49
67	Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 54.	1.2	48
68	Data Sharing Under the General Data Protection Regulation. <i>Hypertension</i> , 2021, 77, 1029-1035.	1.3	47
69	EMPA-REG OUTCOME: The Nephrologist's Point of View. <i>American Journal of Cardiology</i> , 2017, 120, S59-S67.	0.7	46
70	Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2879-2889.	3.0	46
71	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021, 8, 4517-4527.	1.4	46
72	The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2020, 43, 3007-3015.	4.3	45

#	ARTICLE	IF	CITATIONS
73	International Network of Chronic Kidney Disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohorts. <i>BMC Nephrology</i> , 2016, 17, 121.	0.8	44
74	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 1803-1812.	4.3	44
75	Use of a rare disease registry for establishing phenotypic classification of previously unassigned <i>GLA</i> variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup. <i>Journal of Medical Genetics</i> , 2020, 57, 542-551.	1.5	43
76	Kidney Failure Prediction Models: A Comprehensive External Validation Study in Patients with Advanced CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1174-1186.	3.0	43
77	Importance of hyperlipidaemia and therapy in renal patients. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 92-96.	0.4	42
78	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. <i>Kidney International</i> , 2021, 99, 926-939.	2.6	42
79	Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1719-1730.	1.4	41
80	Oxidized LDL Suppresses NF- κ B and Overcomes Protection from Apoptosis in Activated Endothelial Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 456-463.	3.0	41
81	Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1433-1444.	2.2	40
82	Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005875.	1.6	38
83	Mild cognitive impairment and kidney disease: clinical aspects. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 10-17.	0.4	38
84	HDL Cholesterol, Apolipoproteins, and Cardiovascular Risk in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 484-492.	3.0	37
85	Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe. <i>Kidney International</i> , 2018, 93, 1432-1441.	2.6	36
86	Renal replacement therapy in Europe: a summary of the 2011 ERA-EDTA Registry Annual Report. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 227-238.	1.4	35
87	Intestinal Cholesterol Absorption, Treatment With Atorvastatin, and Cardiovascular Risk in Hemodialysis Patients. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2291-2298.	1.2	34
88	Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. <i>European Heart Journal</i> , 2019, 40, 880-886.	1.0	34
89	EMPA-REG OUTCOME: The Nephrologist's Point of View. <i>American Journal of Medicine</i> , 2017, 130, S63-S72.	0.6	33
90	Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 713-715.	2.1	33

#	ARTICLE	IF	CITATIONS
91	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018, 93, 1000-1007.	2.6	32
92	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1261-1269.	0.4	32
93	Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 88.	1.2	29
94	Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2018, 72, 929-936.	1.3	29
95	The impact of symptoms on health-related quality of life in elderly pre-dialysis patients: effect and importance in the EQUAL study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1707-1715.	0.4	29
96	Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the <sc>EMPAâ€REG OUTCOME</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 135-141.	2.2	29
97	Uremia-Specific Alterations in Lipid Metabolism. <i>Blood Purification</i> , 2002, 20, 451-453.	0.9	28
98	Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients. <i>JAMA Internal Medicine</i> , 2022, 182, 592.	2.6	28
99	Association of relative telomere length with cardiovascular disease in a large chronic kidney disease cohort: The GCKD study. <i>Atherosclerosis</i> , 2015, 242, 529-534.	0.4	27
100	Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis. <i>Kidney International</i> , 2016, 89, 1380-1387.	2.6	27
101	Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2019, 42, e53-e55.	4.3	27
102	Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1112-1114.	0.4	27
103	Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy. <i>PLoS ONE</i> , 2015, 10, e0140627.	1.1	27
104	Fabry disease under enzyme replacement therapyâ€”new insights in efficacy of different dosages. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1362-1372.	0.4	24
105	Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. <i>European Journal of Heart Failure</i> , 2019, 21, 386-388.	2.9	24
106	Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. <i>Kidney International</i> , 2015, 88, 1411-1418.	2.6	23
107	Uraemic symptom burden and clinical condition in women and men of 65 years of age with advanced chronic kidney disease: results from the EQUAL study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1189-1196.	0.4	23
108	High Oxalate Concentrations Correlate with Increased Risk for Sudden Cardiac Death in Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2375-2385.	3.0	23

#	ARTICLE	IF	CITATIONS
109	Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 104-111.	1.4	23
110	Ecto-5' -Nucleotidase CD73 (NT5E), vitamin D receptor and FGF23 gene polymorphisms may play a role in the development of calcific uremic arteriolopathy in dialysis patients – Data from the German Calciphylaxis Registry. <i>PLoS ONE</i> , 2017, 12, e0172407.	1.1	23
111	Assessing Global Kidney Nutrition Care. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 38-52.	2.2	23
112	Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes – A Proposed MARE Definition. <i>Kidney International Reports</i> , 2018, 3, 1030-1038.	0.4	22
113	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3025-3035.	1.8	22
114	Fabry disease model: A rational approach to the management of fabry disease. <i>Clinical Therapeutics</i> , 2007, 29, S2-S5.	1.1	21
115	Renal function decline in older men and women with advanced chronic kidney disease – results from the EQUAL study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1656-1663.	0.4	21
116	Lowering cholesterol in chronic kidney disease: is it safe and effective?. <i>European Heart Journal</i> , 2015, 36, 2988-2995.	1.0	20
117	Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2103-2111.	0.4	20
118	High convection volume in online post-dilution haemodiafiltration: relevance, safety and costs. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 368-373.	1.4	18
119	Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1886-1891.	2.2	18
120	Heart Failure in a Cohort of Patients with Chronic Kidney Disease: The GCKD Study. <i>PLoS ONE</i> , 2015, 10, e0122552.	1.1	18
121	Non-high-density lipoprotein cholesterol: A target of lipid-lowering in dialysis patients. <i>American Journal of Kidney Diseases</i> , 2003, 41, S72-S75.	2.1	17
122	Renal replacement therapy in Europe – a summary of the 2009 ERA-EDTA Registry Annual Report. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 109-119.	1.4	17
123	Do telomeres have a higher plasticity than thought? Results from the German Chronic Kidney Disease (GCKD) study as a high-risk population. <i>Experimental Gerontology</i> , 2015, 72, 162-166.	1.2	17
124	Prognostic Value of High-Sensitivity Versus Conventional Cardiac Troponin T Assays Among Patients With Type 2 Diabetes Mellitus Undergoing Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2018, 71, 822-830.	2.1	17
125	Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial. <i>Diabetology International</i> , 2020, 11, 129-141.	0.7	17
126	PROGRESS IN UREMIC TOXIN RESEARCH: C-reactive Protein and Uremia. <i>Seminars in Dialysis</i> , 2009, 22, 438-441.	0.7	15

#	ARTICLE	IF	CITATIONS
127	Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus. <i>Kidney and Blood Pressure Research</i> , 2011, 34, 209-217.	0.9	15
128	Status of periodontal health in German patients suffering from chronic kidney disease—Data from the GCKD study. <i>Journal of Clinical Periodontology</i> , 2020, 47, 19-29.	2.3	15
129	Major adverse renal events (MARE): a proposal to unify renal endpoints. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 491-497.	0.4	15
130	The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 662-674.	2.2	15
131	Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1061-1071.	2.2	15
132	Renal replacement therapy in Europe—a summary of the 2010 ERA—EDTA Registry Annual Report. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 105-115.	1.4	14
133	Time to Revisit the Role of Renal Dietitian in the Dialysis Unit. , 2014, 24, 58-60.		14
134	Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME. <i>ESC Heart Failure</i> , 2020, 7, 3401-3407.	1.4	14
135	Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1062-1073.	2.2	14
136	Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial. <i>American Journal of Kidney Diseases</i> , 2022, 79, 796-806.	2.1	14
137	Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy. <i>Molecular Genetics and Metabolism</i> , 2019, 126, 210-211.	0.5	13
138	Lipid Metabolism in Chronic Kidney Disease: The Role of Statins in Cardiovascular Risk. , 2007, 17, 75-78.		12
139	Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients. <i>Atherosclerosis</i> , 2014, 236, 263-269.	0.4	12
140	Why systematic literature reviews in Fabry disease should include all published evidence. <i>European Journal of Medical Genetics</i> , 2019, 62, 103702.	0.7	12
141	Kidney function and symptom development over time in elderly patients with advanced chronic kidney disease: results of the EQUAL cohort study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 862-870.	0.4	12
142	Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3003-e3007.	1.8	12
143	Uromodulin in the Bloodstream: Old Wine in a New Wineskin. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1955-1957.	3.0	11
144	What Is the Utility of KDIGO Criteria to Identify High-Risk Populations?. <i>American Journal of Kidney Diseases</i> , 2021, 77, 7-8.	2.1	11

#	ARTICLE	IF	CITATIONS
145	Health-Related Quality-of-Life Trajectories over Time in Older Men and Women with Advanced Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 205-214.	2.2	11
146	Fifty years of ERA-EDTA Registry—a registry in transition. <i>Kidney International Supplements</i> , 2015, 5, 12-14.	4.6	10
147	Chronic kidney disease in primary care in Germany. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2017, 25, 223-230.	0.8	10
148	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2020, 76, 109-120.	2.1	10
149	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 291-303.	3.0	10
150	Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers. <i>Frontiers in Pharmacology</i> , 2021, 12, 786706.	1.6	10
151	Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME [®] . <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412097525.	0.9	9
152	Treatment switch in Fabry disease- a matter of dose?. <i>Journal of Medical Genetics</i> , 2021, 58, 342-350.	1.5	9
153	Expert guidance on the multidisciplinary management of cystinosis in adolescent and adult patients. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1675-1684.	1.4	9
154	Postmarketing experience with Neutrolin [®] (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 661-663.	1.3	8
155	Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1469-1480.	0.4	8
156	Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus. <i>Scientific Reports</i> , 2020, 10, 14158.	1.6	8
157	Kidney function assessment and endpoint ascertainment in clinical trials. <i>European Heart Journal</i> , 2022, 43, 1379-1400.	1.0	8
158	Oxygen-derived radicals stimulate renin release of isolated juxtaglomerular cells. <i>FEBS Letters</i> , 1994, 351, 314-316.	1.3	7
159	The future of European Nephrology 'Guidelines'—a declaration of intent by European Renal Best Practice (ERBP). <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 213-221.	1.4	7
160	Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease. , 2014, 24, 65-71.		7
161	Effect of High-Flux Dialysis on Circulating FGF-23 Levels in End-Stage Renal Disease Patients: Results from a Randomized Trial. <i>PLoS ONE</i> , 2015, 10, e0128079.	1.1	7
162	Left Ventricular Structure in Patients With Mild-to-Moderate CKD—a Magnetic Resonance Imaging Study. <i>Kidney International Reports</i> , 2019, 4, 267-274.	0.4	7

#	ARTICLE	IF	CITATIONS
163	Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study. CKJ: Clinical Kidney Journal, 2021, 14, 1770-1779.	1.4	7
164	Survey about do-it-yourself closed loop systems in the treatment of diabetes in Germany. PLoS ONE, 2020, 15, e0243465.	1.1	7
165	Association of Serum Phosphate with Efficacy of Statin Therapy in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 546-554.	2.2	7
166	Single Nucleotide Variants in the Protein C Pathway and Mortality in Dialysis Patients. PLoS ONE, 2014, 9, e97251.	1.1	6
167	Kidneys do not like excess body fat. Lancet Diabetes and Endocrinology, the, 2015, 3, 669-671.	5.5	6
168	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation, 2018, 33, gfw396.	0.4	6
169	Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. Therapeutics and Clinical Risk Management, 2017, Volume 13, 69-79.	0.9	6
170	Funding kidney research as a public health priority: challenges and opportunities. Nephrology Dialysis Transplantation, 2020, , .	0.4	6
171	A scoring system for predicting individual treatment effects of statins in type 2 diabetes patients on haemodialysis. European Journal of Preventive Cardiology, 2021, 28, 838-851.	0.8	6
172	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. CKJ: Clinical Kidney Journal, 2021, 14, 226-236.	1.4	6
173	Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy: A Post Hoc Analysis from the SONAR Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 2731-2734.	3.0	6
174	Calculating the Rate of Senescence From Mortality Data: An Analysis of Data From the ERA-EDTA Registry. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 468-474.	1.7	5
175	The Obesity Paradox and the Role of Inflammation. Journal of the American Society of Nephrology: JASN, 2016, 27, 1270-1272.	3.0	5
176	Long-Term Survivor Characteristics in Hemodialysis Patients with Type 2 Diabetes. American Journal of Nephrology, 2018, 47, 30-39.	1.4	5
177	A new era in therapeutics for diabetic kidney disease. Nature Reviews Nephrology, 2018, 14, 78-80.	4.1	5
178	CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle. Diabetes Research and Clinical Practice, 2019, 153, 30-40.	1.1	5
179	Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. Nephrology Dialysis Transplantation, 2020, 35, 1761-1769.	0.4	5
180	Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. Circulation, 2021, 144, 1265-1267.	1.6	5

#	ARTICLE	IF	CITATIONS
181	The relationship between uremic toxins and symptoms in older men and women with advanced chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 798-807.	1.4	5
182	Hemoglobin Cycling in Hemodialysis Patients. Nephrology Research & Reviews, 2010, 2, 1-5.	0.2	4
183	Should we aim for oral health to improve outcomes in chronic kidney disease?. Nephrology Dialysis Transplantation, 2016, 31, 1551-1554.	0.4	4
184	FP411THE ASSOCIATION BETWEEN RENAL FUNCTION AND TROPONIN T OVER TIME IN STABLE CKD PATIENTS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	4
185	<i>Lancet</i> Countdown paper: what does it mean for nephrology?. Nephrology Dialysis Transplantation, 2019, 34, 4-6.	0.4	4
186	Comparison of different algorithms for the assessment of cardiovascular risk after kidney transplantation by the time of entering waiting list. CKJ: Clinical Kidney Journal, 2020, 13, 150-158.	1.4	4
187	Not only incretins for diabetic kidney diseaseâ€”beneficial effects by DPP-4 inhibitors. Kidney International, 2021, 99, 318-322.	2.6	4
188	Comparison of Static and Dynamic Baseline Creatinine Surrogates for Defining Acute Kidney Injury. Nephron, 2021, 145, 1-11.	0.9	4
189	Lipids in end-stage renal disease. Journal of Nephrology, 2002, 15, 202-4.	0.9	4
190	Associations between depressive symptoms and disease progression in older patients with chronic kidney disease: results of the EQUAL study. CKJ: Clinical Kidney Journal, 2022, 15, 786-797.	1.4	4
191	What Are the Causes and Consequences of the Chronic Inflammatory State in Chronic Dialysisâ€”Patients?. Seminars in Dialysis, 2001, 13, 174-175.	0.7	3
192	Prospective cohort studies of beta-trace protein and mortality in haemodialysis patients and patients undergoing coronary angiography. Nephrology Dialysis Transplantation, 2018, 33, 1984-1991.	0.4	3
193	CREDENCE and DELIGHT deliver on renal benefits. Nature Reviews Nephrology, 2019, 15, 459-460.	4.1	3
194	Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus. CKJ: Clinical Kidney Journal, 2022, 15, 1915-1923.	1.4	3
195	Total Nutrition Therapy Renal: A Clinical Nutrition Education Program for Nephrologists and Other Renal Health Care Professionals. , 2014, 24, 347-348.		2
196	A Janusâ€”headed electrolyte and â€”RALES' diseaseâ€”TM. ESC Heart Failure, 2017, 4, 195-197.	1.4	2
197	The nephrology crystal ball: the medium-term future. Nephrology Dialysis Transplantation, 2019, 35, 222-226.	0.4	2
198	FP117SAFETY AND EFFICACY OF BARDOXOLONE METHYL IN PATIENTS WITH RARE CHRONIC KIDNEY DISEASES. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	2

#	ARTICLE	IF	CITATIONS
199	Lipid Disorders in Diabetic Nephropathy. , 0, , 175-192.		1
200	Virtual reality: the dawn of a new ERA. Nephrology Dialysis Transplantation, 2021, 36, 1-4.	0.4	1
201	MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	1
202	COVID-19 and the kidney: A retrospective analysis of 37 critically ill patients using machine learning. PLoS ONE, 2021, 16, e0251932.	1.1	1
203	Dyslipidemia in Chronic Kidney Disease. , 0, , 333-344.		0
204	FP593REAL-WORLD SAFETY AND EFFECTIVENESS OF SUCROFERRIC OXYHYDROXIDE IN DIALYSIS PATIENTS: AN INTERIM ANALYSIS OF THE VERIFIE STUDY. Nephrology Dialysis Transplantation, 2018, 33, i242-i242.	0.4	0
205	FO047REAL-WORLD EFFECTIVENESS OF SUCROFERRIC OXYHYDROXIDE FOR SERUM PHOSPHORUS CONTROL IN DIALYSIS PATIENTS: AN INTERIM SUBGROUP ANALYSIS OF THE VERIFIE STUDY. Nephrology Dialysis Transplantation, 2018, 33, i37-i38.	0.4	0
206	SP294THE EQUAL COHORT STUDY - KIDNEY FUNCTION AND SYMPTOM TRAJECTORY OVER TIME IN PREDIALYSIS ADVANCED CKD PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i443-i443.	0.4	0
207	SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL. Nephrology Dialysis Transplantation, 2018, 33, i487-i487.	0.4	0
208	Management of type 2 diabetes in renal diseaseâ€”the twilight of the gods. Nephrology Dialysis Transplantation, 2019, 34, 231-233.	0.4	0
209	FO055EVALUATION OF PREDICTION MODELS FOR PROGRESSION OF CHRONIC KIDNEY DISEASE TO KIDNEY FAILURE: A COMPREHENSIVE EXTERNAL VALIDATION STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
210	FC024REAL-WORLD SAFETY AND EFFECTIVENESS OF SUCROFERRIC OXYHYDROXIDE IN PATIENTS UNDERGOING PERITONEAL DIALYSIS: AN INTERIM ANALYSIS OF THE VERIFIE STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
211	FP392DYNAMIC PREDICTION OF MORTALITY IN ADVANCED CKD USING TROPONIN T. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
212	Response to Gurevich and colleagues: The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Molecular Genetics and Metabolism Reports, 2019, 20, 100493.	0.4	0
213	The authors reply. Kidney International, 2020, 97, 213-214.	2.6	0
214	SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA. Journal of the Endocrine Society, 2019, 3, .	0.1	0
215	Present and future of CONNECT: a new and compelling project of modern medicine. Nephrology Dialysis Transplantation, 2021, 37, ii1-ii3.	0.4	0
216	From WEDA to EDTA to ERA: 60 years of supporting European Nephrology and counting. Nephrology Dialysis Transplantation, 2022, , .	0.4	0